Wide Ranks

ETNB

89bio, Inc.

9.14

Top Statistics
Market Cap 1 B Forward PE -3.14 Revenue Growth 0.00 %
Current Ratio 11.66 Trailing PE 0.0000 Earnings Growth 0.00 %
Profit Margins 0.00 % Peg Ratio Dividend Yield 0.00 %
Enterprice / EBITA -1.92 Enterprise / Revenue Price To Sales Trailing12 Months
Profitability
Profit Margins 0.00 % Operating Margins
Balance Sheet
Total Cash 423 M Total Cash Per Share 3.99 Total Debt 37 M
Total Debt To Equity 9.94 Current Ratio 11.66 Book Value Per Share 3.56
All Measures
Short Ratio 655.00 % Message Board Id finmb_640272057 Shares Short Prior Month 5 M
Return On Equity -0.7331 City San Francisco Uuid 6271fd18-e443-39f3-b14c-3361d6248f55
Previous Close 8.90 First Trade Date Epoch Utc 1 B Book Value 3.56
Beta 0.9780 Total Debt 37 M Volume 338740
Price To Book 2.57 Fifty Two Week Low 7.00 Total Cash Per Share 3.99
Shares Short Previous Month Date 1 B Target Median Price 29.50 Max Age 86400
Recommendation Mean 1.56 Sand P52 Week Change 0.3133 Target Mean Price 30.12
Net Income To Common -288960000 Short Percent Of Float 0.0587 Implied Shares Outstanding 117 M
Trailing Peg Ratio None Last Fiscal Year End 1 B Average Daily Volume10 Day 943040
Average Volume10days 943040 Total Cash 423 M Next Fiscal Year End 1 B
Held Percent Insiders 0.0059 Trailing PE 0.0000 Date Short Interest 1 B
Most Recent Quarter 1 B Regular Market Previous Close 8.90 Target Low Price 12.00
Gmt Off Set Milliseconds -18000000 Fifty Day Average 8.22 Open 8.93
Free Cashflow -180680752 State CA Dividend Yield 0.00 %
Return On Assets -0.4136 Time Zone Short Name EST Trailing Eps -2.96
Day Low 8.77 Address1 142 Sansome Street Shares Outstanding 117 M
Price Hint 2 Target High Price 49.00 Website https://www.89bio.com
52 Week Change 0.1368 Average Volume 697101 Forward Eps -2.87
Recommendation Key buy Compensation As Of Epoch Date 1 B Quick Ratio 1083.00 %
Is_sp_500 False Regular Market Day High 9.18 Profit Margins 0.00 %
Debt To Equity 9.94 Fifty Two Week High 16.63 Day High 9.18
Shares Short 5 M Regular Market Open 8.93 Industry Key biotechnology
Earnings Growth 0.00 % Revenue Growth 0.00 % Shares Percent Shares Out 0.0469
Operating Cashflow -280536000 Currency USD Time Zone Full Name America/New_York
Market Cap 1 B Is_nasdaq_100 False Zip 94104
Quote Type EQUITY Industry Biotechnology Long Name 89bio, Inc.
Regular Market Day Low 8.77 Held Percent Institutions 0.9367 Current Price 9.14
Address2 Second Floor Enterprise To Ebitda -1.92 Financial Currency USD
Current Ratio 11.66 Industry Disp Biotechnology Number Of Analyst Opinions 8
Country United States Float Shares 68 M Two Hundred Day Average 9.07
Enterprise Value 583 M Forward PE -3.14 Regular Market Volume 338740
Ebitda -303812000 Exchange NGM
Go to Yahoo Finance Go to Seeking Alpha 
89bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases.

Its lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis; and for the treatment of severe hypertriglyceridemia.

The company was incorporated in 2018 and is headquartered in San Francisco, California.